Hi, I’m Melissa Palmer, MD — an internationally renowned Hepatologist. I’m a Liver Disease consultant to the pharmaceutical and biotech industries
Melissa Palmer, MD has been a hepatologist since 1988. She was in a solo practice devoted to treating and evaluating patients with liver disease until 2009 at which time she became Cinical professor NYU Langone Director of Hepatology at NYU Plainview. During that time she served as a consultant to > 25 industry -associated companies as an expert on all aspects of liver disease from drug development to commercialization. Dr. Palmer left NYU to become Senior Vice President of Clinical Research and Head of Hepatology at Kadmon Corporation. After 1 year Dr. Palmer was promoted to Global Head of Hepatology, and became Senior Vice President of Pharmacovigilance in addition to SVP of Clinical Research.
Dr. Palmer left Kadmon in 2015 to be the clinical lead on their NASH program, as well as to consult on other liver-related issues within the company, such as cholestatic liver disease and liver-related safety issues, and was soon promoted to Global Development Lead – Hepatology. Shire was acquired by Takeda in 2019 and Dr. Palmer was made Head of Liver Disease Development at Takeda.
From Dec. 2020–to March 2022 Melissa Palmer, MD was the Chief Medical Officer of Gannex Pharma, a wholly owned company of Ascletis Pharma.
Dr. Palmer graduated from Columbia University with a B.A. and was trained in Hepatology (as well as medical school) at the Mount Sinai School of Medicine in New York City. She has authored numerous medical and lay-public book and book chapters and contributed to three encyclopedias on various liver-related topics. Her scientific publications in the field of Hepatology have appeared in such peer-reviewed journals as Hepatology, Gastroenterology, Seminars of Liver Disease, Transplantation, AP&T and she is a contributing editor of several peer-reviewed journals.
Melissa Palmer MD is the CEO of Liver Consulting LLC
Specialties: Hepatology Nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) Liver Disease, Clinical Research, Pharmacovigilance, Drug Development, Cholestatic Liver disease, Drug-Induced Liver Injury.
Contact Melissa Palmer, MD at email@example.com